As global biopharmas expand into new markets, they introduce more systems to handle increasing data volumes and business operations, building layers of disconnected data, systems, and processes. While ...

Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

Brii Biosciences and Joincare Pharmaceutical have signed a licence and technology transfer agreement for BRII-693 for MDR/XDR infections.